Dark Forest Capital Management LP acquired a new stake in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 50,782 shares of the company's stock, valued at approximately $1,178,000.
Several other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Option Care Health by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company's stock worth $448,118,000 after purchasing an additional 75,313 shares during the last quarter. Wellington Management Group LLP raised its holdings in Option Care Health by 84.6% in the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company's stock worth $425,143,000 after buying an additional 8,400,208 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Option Care Health by 17.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock worth $92,518,000 after buying an additional 591,042 shares in the last quarter. Norges Bank bought a new position in shares of Option Care Health in the fourth quarter worth approximately $60,219,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Option Care Health by 6.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,510,131 shares of the company's stock valued at $58,235,000 after acquiring an additional 147,054 shares in the last quarter. 98.05% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several brokerages have commented on OPCH. JPMorgan Chase & Co. increased their target price on Option Care Health from $40.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Jefferies Financial Group upgraded Option Care Health from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. JMP Securities restated a "market outperform" rating and set a $36.00 target price on shares of Option Care Health in a research note on Tuesday. Barrington Research reiterated an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a research note on Monday. Finally, Bank of America raised shares of Option Care Health from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $26.00 to $33.00 in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Option Care Health currently has an average rating of "Moderate Buy" and an average target price of $33.75.
Get Our Latest Report on OPCH
Option Care Health Trading Up 1.9 %
Shares of Option Care Health stock opened at $32.14 on Thursday. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53. The company's fifty day simple moving average is $33.33 and its 200-day simple moving average is $28.70. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The stock has a market capitalization of $5.28 billion, a PE ratio of 27.01, a P/E/G ratio of 2.30 and a beta of 1.07.
Insider Buying and Selling
In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of the company's stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the sale, the insider now owns 44,974 shares in the company, valued at $1,495,835.24. This represents a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.64% of the stock is owned by insiders.
About Option Care Health
(
Free Report)
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Option Care Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Option Care Health wasn't on the list.
While Option Care Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.